Exabis Library
Welcome to the e-CCO Library!
P311: Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn’s disease patients achieving endoscopic remission
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P311: Microscopic inflammation and myenteric plexitis at the margin of resection do not predict endoscopic recurrence in patients with Crohn's disease after ileocolic resection
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P311: No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term results
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P311: Pharmacokinetics and exposure–response relationships of intravenously administered ustekinumab during induction treatment in patients with ulcerative colitis: Results from the UNIFI induction study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P311: Reliability of computed tomography enterography for evaluation of stricturing Crohn's disease: Development of a Crohn's disease stricture index
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P312 Introduction of bowel ultrasonography for follow-up of paediatric inflammatory bowel disease: A single-centre experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P312: Combination corticosteroids with 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: A multi-center randomized controlled trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P312: Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P312: Erythrocyte methotrexate polyglutamate concentrations in patients with Crohn's Disease: towards a new therapeutic drug monitoring tool
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P312: Has IBD specialists’ awareness of biosimilar monoclonal antibodies changed? Results from a survey amongst ECCO members
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P312: Retrospective study using ultrasonography in predicting clinical relapse of Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P312: The value of faecal biomarkers for screening small bowel inflammation in patients with Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P312: Trabecular bone score in patients with inflammatory bowel diseases
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P313 Time to second pouchitis episode in a Dutch academic cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P313: Comparison of accelerated infliximab induction versus standard induction treatment in acute severe ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P313: Glycan antibodies and pANCA in newly diagnosed inflammatory bowel disease patients at presentation and during follow-up
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P313: Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P313: Long-term durability and safety of anti-TNF agents compared with change to a different mechanism of action as a second-line biological treatment after first anti-TNF failure in Crohn´s disease: results from the Andalusian CambiaCrohn study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P313: Steroid and opioid use among Crohn’s patients before and after initiation of ustekinumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P313: Understanding Inflammatory Bowel Disease patients' experiences, expectations, and insights in identifying and managing anxiety and depression.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM